European stocks rise, with EU leaders slated to resume bailout talks

After the S&P 500 SPX,
+ 0.28%
advanced 1.25% last week, futures on the Dow Jones Industrial Average YM00,
-0.10%
slipped 146 points.

Attention was paid to Brussels, where a two-day meeting of European leaders became four, with talks scheduled to resume in the afternoon.

Reports suggest that leaders may agree to grants worth € 390 billion in a fund that could be worth between € 700 billion and € 750 billion. “That the summit is heading to its fourth day could be a good sign. He suggests that an agreement is already possible at this summit, at least in parts of what is on the table, “said Florian Hense, European economist at Berenberg Bank.

In addition to the Brussels summit, EU negotiators are in London on Monday for a fifth round of negotiations on the UK’s exit from the trade bloc.

The coronavirus is also a focus, and UK Prime Minister Boris Johnson over the weekend compared a second blockade to a nuclear deterrent. Coronavirus numbers in the United States have stagnated, with new cases of about 64,000 on Sunday.

GlaxoSmithKline GSK,
-0.61%
Shares fell 1% after agreeing to pay CureVac up to £ 866 million, in a deal that gives the UK pharmaceutical giant a nearly 10% stake in German biotechnology known for its vaccine capabilities.

AstraZeneca AZN,
+ 2.32%
It increased by 2% before the publication of an expected study in The Lancet on the University of Oxford coronavirus vaccine to be distributed.

Enzymatica ENZY shares,
+ 74.07%
It increased 77% when the company said preliminary results show the ability of ColdZyme oral spray, in vitro, to inactivate SARS-CoV-2, the virus that causes the COVID-19 pandemic.

Philips PHIA,
+ 4.73%
it increased nearly 5% after better-than-expected second-quarter earnings.

UBI UBI Banking,
+ 12.69%
Shares soared 13% when Intesa Sanpaolo added a cash component to its takeover offer.